Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.62 |
| ▸ | SELL | P14151 | 1/20 | 0.62 |
| ▸ | MAG | P20916 | 9/20 | 0.62 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.60 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.52 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356627 | 1.00 | SELP (0.62) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL17300130 | 1.00 | SELP (0.62) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29533149 | 0.95 | SELL (0.62) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29425234 | 0.95 | SELL (0.62) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29454806 | 0.95 | SIGLEC7 (0.66) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29393136 | 0.95 | SIGLEC7 (0.66) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29355980 | 0.95 | SIGLEC7 (0.66) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL30483871 | 0.94 | SIGLEC7 (0.65) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29732819 | 0.94 | SIGLEC7 (0.65) | SELPSELLMAGSIGLEC7NANP | |
| SCHEMBL29432515 | 0.94 | SELL (0.68) | SELPSELLMAGSIGLEC7NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702138-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | Inbiose N.V. (BE) | 2026-03-04 | — | — | EP | claimed |
| EP-4651963-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | Inbiose N.V. (BE) | 2025-11-26 | — | — | EP | claimed |
| WO-2025088103-A1 | PRODUCTION OF A SIALYLATED COMPOUND | INBIOSE N.V. (BE) | 2025-05-01 | — | — | WO | claimed |
| WO-2025088102-A1 | PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE COMPRISING GAL-β1,3-[NEU5AC-A2,6]-HEXNAC-R | INBIOSE N.V. (BE) | 2025-05-01 | — | — | WO | claimed |
| WO-2025078556-A1 | IMPROVED CARBOHYDRATE COUPLING | TACALYX GMBH (DE) | 2025-04-17 | — | — | WO | claimed |
| WO-2024223815-A1 | PRODUCTION OF A NEGATIVELY CHARGED OLIGOSACCHARIDE BY A CELL | INBIOSE N.V. (BE) | 2024-10-31 | — | — | WO | claimed |
| WO-2024153788-A1 | PURIFICATION OF AN OLIGOSACCHARIDE OR OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2024-07-25 | — | — | WO | claimed |
| EP-4396583-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | Glycanostics s.r.o. (SK) | 2024-07-10 | — | — | EP | claimed |
| US-20240191270-A1 | FERMENTATIVE PRODUCTION | INBIOSE N.V. (BE) | 2024-06-13 | — | — | US | claimed |
| EP-4298237-A1 | SINGLE CELL GLYCAN PROFILING | 10X Genomics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023041565-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-23 | — | — | WO | claimed |
| WO-2022182672-A1 | SINGLE CELL GLYCAN PROFILING | 10X GENOMICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| EP-4025601-A1 | SSEA-4 BINDING MEMBERS | Scancell Limited (GB) | 2022-07-13 | — | — | EP | claimed |
| WO-2022057444-A1 | SUGAR CHAIN AND COMPOSITIONS THEREOF AND USE THEREOF IN PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTION | 中国科学院过程工程研究所 | 2022-03-24 | — | — | WO | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| EP-4742901-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743567-A1 | CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2022034077-A1 | PRODUCTION OF ALPHA-1,3 GLYCOSYLATED FORM OF FUC-A1,2-GAL-R | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022034075-A1 | PRODUCTION OF GLCNAC CONTAINING BIOPRODUCTS IN A CELL | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022034076-A2 | PRODUCTION OF GALACTOSYLATED DI- AND OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | SELP 621/4885SELL 599/4885MAG 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.